The Non-$mall Cost of Non-Small Cell Lung Cancer
|
|
- Augustus Hill
- 6 years ago
- Views:
Transcription
1 The Non-$mall Cost of Non-Small Cell Lung Cancer CPT Zachary Leftwich, PharmD PHY-1 Managed Care Pharmacy Resident Defense Health Agency Pharmacy Operations Division, San Antonio, TX May 4 th 2018 At the end of this session, the learner will be able to: 1. Summarize the pathophysiology of non-small cell lung cancer 2. Analyze current guideline recommendations for treating non-small cell lung cancer 3. Evaluate similarities and differences between clinical trial results and real-world data 1
2 Assessment questions: 1. Which ALK inhibitor is preferred for first-line in ALK+ NSCLC? a) Alectinib b) Brigatinib c) Crizotinib d) Ceritinib 2. Which agent carries the highest risk of Interstitial lung disease? a) Alectinib b) Brigatinib c) Crizotinib d) Ceritinib 3. Military health system patients on crizotinib experienced longer durations of therapy and better survival than clinical trial patients. True False Speaker Disclosure: CPT Zachary Leftwich has nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation. The findings discussed in this presentation represent the views of the authors, and do not necessarily reflect the views of the Department of Defense (DoD), nor the Departments of the Army, Navy, and Air Force. 2
3 Background 1. Lung Cancer 1 a. Represents the second most common form of cancer b. 234,030 new cases, and 154,050 deaths from lung cancer annually c. Average age at the time of diagnosis is 70 years d. Risk factors include: smoking, genetics, radon exposure, pollution, asbestos, exhaust 2. Non-small cell lung cancer (NSCLC) 1 a. Represents around 85% of all lung cancers b. Smoking is the major risk factor c. There are a wide range of prognoses associated with NSCLC. Early stages may be curable, while later metastatic stages are not i. Five year survival rate for stage IA is 92% ii. Stage IVA five year survival is 10% d. Typically presents as an adenocarcinoma 3. Anaplastic Lymphoma Kinase (ALK) rearrangement positive non-small cell lung cancer 1,2 a. Represents 3-6% of patients with NSCLC b. Most patients are never smokers, or former smokers c. Average age at diagnosis is 52 d. Currently four treatments available for this subset of NSCLC ALK-positive non-small cell lung cancer pathophysiology 1. Normal Physiology 2,3 a. ALK is a tyrosine kinase enzyme that protects lung cells from degradation and apoptosis when phosphorylated (Fig 1) 2. ALK rearrangement pathophysiology 2,3 a. ALK rearrangement is a t (2;5) translocation. This enables phosphoprotein nucleophosmin to auto phosphorylate without activation by a ligand (Fig 2) Figure 1. Normal ALK physiology 2 Figure 2. ALK rearrangement pathophysiology 2 3
4 Treatment methods 1. Historic treatment for advanced metastatic NSCLC consisted of chemotherapy 4 a. Preferred chemotherapy options included: Pemetrexed (500mg/m 2 ) + cisplatin (75mg/m 2 ) Pemetrexed (500mg/m 2 ) + carboplatin (target AUC: 5-6mg/mL/minute) 2. Modern treatment for advanced metastatic NSCLC includes ALK inhibitors 5 a. Available ALK inhibitors are listed in Table 1 below 5-9 Table 1. Currently available ALK inhibitors b. Strengths of ALK inhibitor therapy include i. Less severe adverse reactions compared to chemotherapy ii. No patient requirement to travel to an infusion clinic iii. All ALK inhibitors are available as oral capsules or tablets c. Weakness of ALK inhibitor therapy include 4 i. Expense of treatment can be cost prohibitive. ALK inhibitor therapy costs in excess of $10,000 per month ii. There is a limited pool of clinical trial data available due to the recent FDA approval of the agents within the class ALK inhibitor mechanism of action 1. ALK inhibitors exert their effect directly on the anaplastic lymphoma kinase enzyme 2,12 a. ALK inhibitors bind to the tyrosine-kinase portion of the ALK enzyme to prevent the binding of ATP (Fig 3) b. The ALK enzyme is unable to auto phosphorylate without access to the ATP binding site c. Resistance to ALK inhibitor treatment commonly occurs within one year of treatment due to gene amplification or secondary mutations 4
5 Figure 3. ALK inhibitor mechanism of action 2 Role of ALK inhibitors in NSCLC 1. ALK inhibitors extend progression-free survival by slowing cancer progression 5 a. ALK inhibitors are the preferred first-line agent in advanced metastatic NSCLC b. Chemotherapy initiation is delayed until the cancer progresses while on ALK inhibitor treatment c. When cancer progresses during ALK inhibitor therapy, the oncologist may switch to another ALK inhibitor, or initiate chemotherapy ALK Inhibitor adverse reactions and pharmacokinetics 1. ALK inhibitor adverse drug reactions are often less severe than chemotherapy adverse reactions6-11, 13 a. Crizotinib has a higher incidence of vision disorder, diarrhea, and edema when compared to chemotherapy b. Chemotherapy is associated with a higher frequency of more severe adverse effects including anemia, neutropenia, leukopenia, and thrombocytopenia c. Interstitial lung disease (ILD) is a rare but serious adverse drug reaction that can occur while on ALK inhibitor therapy i. Brigatinib is the ALK inhibitor with the highest risk of ILD (9.1%) ii. Management of ILD varies between drugs, but generally requires a dose reduction or discontinuation of the offending agent d. All ALK inhibitors are associated with a risk of vision disorder development including: diplopia, photophobia, impaired vision, and reduced acuity 14 i. Crizotinib has the highest incidence of vision disorders ii. Switch to another ALK inhibitor upon onset of severe vision loss to prevent permanent visual impairment e. Crizotinib and ceritinib carry a high risk for nausea, vomiting and diarrhea i. The rates of nausea, vomiting and diarrhea rival the highly emetogenic chemotherapy alternative to ALK inhibitors ii. Alectinib and brigatinib are less emetogenic and are options to consider if crizotinib or ceritinib are intolerable 5
6 Table 2. ALK inhibitor adverse drug reactions ALK inhibitors are primarily metabolized hepatically (Table 3) a. Brigatinib is the only ALK inhibitor that utilizes CYP 2C8 for metabolism b. Ceritinib and alectinib are exclusively excreted in the feces; crizotinib and brigatinib are also excreted in urine c. The time to response is similar among the agents and range between months13, Table 3. ALK inhibitor pharmacokinetics Time to response= Date of randomization to the date of partial or complete response Current guideline recommendations 1. Patients diagnosed with advanced metastatic NSCLC should undergo histologic and molecular testing 5 a. Mutation testing should include ALK, epidermal growth factor receptor, C-ros oncogene, B-Raf, and programmed death-ligand 1 b. ALK inhibitors are first-line therapy in ALK mutation-positive patients who have not started a course of chemotherapy c. Alectinib is the preferred first-line ALK inhibitor 6
7 Clinical question What benefit can a patient in a real-world setting expect to receive from crizotinib? 1. Solomon, B et al. (2014) 13 PROFILE 1014: First-Line Crizotinib Versus Chemotherapy in ALK-Positive Lung Cancer Objective Study Design Report the results of a comparison between crizotinib and pemetrexed-plus-platinum chemotherapy Randomized phase 3, open-label, head-to-head clinical trial Outcomes Treatment Primary Progression-Free Survival (PFS) Crizotinib 250mg Twice Daily Secondary Objective Response Rate (ORR) Overall Survival (OS) Pemetrexed (500mg/m2) + Cisplatin: 75mg/m2 OR Carboplatin: AUC: 5-6mg/mL/min Definitions Statistics Patient Population Inclusion Criteria ECOG Score: Eastern Cooperative Oncology Group Score PFS: Median time until death or disease progression OS: Median time from treatment initiation to death Hazard ratios: Cox regression analysis Time to endpoints analysis: Kaplan-Meier method (PFS/OS) Objective response rate: Pearson chi-square test Total patients (343) crizotinib (172) chemotherapy (171) Stratified by: ECOG score, Asian race, presence of brain metastases Age>18 Diagnosed advanced, recurrent, or metastatic ALK(+) NSCLC No previous systemic treatment Response Evaluation Criteria in Solid Tumors (RECIST) measurable Eastern Cooperative Oncology Group (ECOG) score of 0-2 Adequate hepatic, renal, and bone marrow function 7
8 Baseline Patient Characteristics Measure Crizotinib (n=172) Chemotherapy (n=171) Median Age (Range) 52 (22-76) 54 (19-78) ECOG Score n (%) 0-1: 161 (94%) 2: 10 (6%) 0-1: 163 (95%) 2: 8 (5%) Brain Metastases: n (%) 45 (26%) 47 (27%) Smoking status: n (%) Never smoked: 106 (62) Former smoker: 56 (33) Current smoker: 10 (6) Never smoked: 112 (65) Former smoker: 54 (32) Current smoker: 5 (3) Results Result Crizotinib (n=172) Chemotherapy (n=171) Progression-Free Survival Median Months, (95% CI) 10.9 Months ( ) 7 Months ( ) Hazard Ratio (95%CI) 0.45 ( ) - Objective Response Rate %, (95% CI) 74% (67-81) 45% (37-53) 12 Month Mortality 16% (28/172) 21% Duration of Therapy Median Months, (Range) Duration of Response Median Months, (95% CI) 10.9 Months ( ) 11.3 Months ( ) 4.1 Months ( ) 5.3 Months ( ) Patients Remaining at Data Cutoff
9 Author s Conclusion Results were independent of: Type of platinum treatment Performance status Patient ethnicity Presence of brain metastases Overall survival did not differ significantly between treatments Crizotinib is superior to chemotherapy with respect to PFS, ORR, reduction of symptoms, and quality of life In patients with previously untreated ALK+ NSCLC Reviewer s Critique Strengths Limitations Phase 3 clinical trial Head-to-head vs. standard of care Relatively large scale study Open Label Crossover could have boosted chemotherapy mortality results Overall survival data is immature Funded by Pfizer Only 18/343 patients were ECOG 2. Authors claim performance status had no effect on outcomes 9
10 2. Peters, s et al. (2017) 20 ALEX: Alectinib Versus Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer Objective Study Design Investigate alectinib compared with crizotinib in patients with untreated, advanced ALK+ NSCLC. Randomized, open-label, phase 3, head-to-head clinical trial Primary Secondary Outcomes Treatment Definitions Statistics Progression-Free Survival (PFS) Alectinib 600 mg Twice daily Objective Response Rate (ORR) Overall Survival (OS) Time to CNS Progression Crizotinib 250mg Twice Daily ECOG Score: Eastern Cooperative Oncology Group Score PFS: Median time until death or disease progression OS: Median time from treatment initiation to death Hazard ratios: Cox regression analysis Time to endpoints analysis: Kaplan-Meier method (PFS/OS) Objective response rate: Clopper-Pearson method Patient Population Total patients (303) alectinib (152) crizotinib (151) Stratified by: ECOG score, Asian race, presence of brain metastases Inclusion Criteria Age>18 Diagnosed advanced, recurrent, or metastatic ALK(+) NSCLC No previous systemic treatment Response Evaluation Criteria in Solid Tumors (RECIST) measurable Eastern Cooperative Oncology Group (ECOG) score of 0-2 Adequate hepatic, renal, and bone marrow function Baseline Patient Characteristics Measure Alectinib (n=152) Crizotinib (n=151) Median Age (Range) 58 (25-88) 54 (18-91) ECOG Score n (%) 0-1: 142 (95%) 2: 10 (7%) 0-1: 141 (93%) 2: 10 (7%) Brain Metastases: n (%) 64 (42%) 58 (38%) 10
11 Smoking Status: n (%) Nonsmoker: 92 (61) Former smoker: 48 (32) Current smoker: 12 (8) Nonsmoker: 98 (65) Former smoker: 48 (32) Current smoker: 5 (3) Results Result Alectinib (n=152) Crizotinib (n=151) Progression-Free Survival Median Months, (95% CI) 25.7 Months ( NE) 10.4 Months ( ) Hazard Ratio (95%CI) 0.50 ( ) - Objective Response Rate %, (95% CI) 82.9% ( ) 75.5% ( ) 12 Month Mortality 15.6% (24/152) 17.5% (26/151) Duration of Therapy Median Months, (Range) Duration of Response Median Months, (95% CI) 17.9 Months (0-29) NE 10.7 Months (0-27) 11.1 Months (7.9-13) Patients Remaining at Data Cutoff Author s Conclusion Progression-free survival was significantly longer with alectinib than with crizotinib Time to CNS progression was significantly longer with alectinib Grade 3-5 adverse events were more frequent with crizotinib than with alectinib Reviewer s Critique Strengths Limitations Phase 3 clinical trial Head-to-head vs. standard of care Large scale study Addressed effect of ECOG performance status on outcomes Open Label Overall survival data is immature Only 20/303 patients were ECOG 2 11
12 Real-world utilization in the Military Health System (MHS) 1. TRICARE is the health plan that serves over 9.4 million active duty and retired military members and their families a. Prescriptions are dispensed from retail pharmacies, military treatment facilities, and a mail order pharmacy b. The pharmacy expenditure exceeds $7.6 billion annually, and includes the drugs covered under the outpatient pharmacy benefit c. The Defense Health Agency (DHA) oversees the execution of the budget and the management of the formulary for the Department of Defense (DoD) 1. Leftwich, Z, Lugo M, Trice, S, Khoury R. (2018) Real-World Utilization of Oral Non-Small Cell Lung Cancer & Ovarian Cancer Agents in the Military Health System Objective Study Design Outcomes Treatment Definitions Statistics Patient Population N= 217 (crizotinib group) Inclusion Criteria Describe similarities and differences in duration of therapy, mortality and time to treatment change between clinical trial data and the MHS population Retrospective pharmacy claims analysis Primary Duration of therapy (DOT) Twelve month mortality Secondary Time to treatment change ALK Inhibitors: crizotinib, ceritinib, alectinib, brigatinib ECOG Score: Eastern Cooperative Oncology Group Score DOT: Median time until treatment discontinuation Twelve month mortality: Proportion of patients who did not survive 12 months of treatment Twelve month mortality: Kaplan-Meier method *The authors did not perform statistical comparisons between groups due to the presence of confounders between patient populations Crizotinib: 217 Ceritinib: 6 Alectinib: 13 Brigatinib: 0 Required ICD-9 or 10 code from Oct 2012 to Oct for: Lung cancer (ALK inhibitors) Prescription (Rx) claims for ALK inhibitors during the same timeframe, and all prior prescriptions 12
13 Baseline Patient Characteristics Measure Crizotinib (n=181) Median Age: Years, (Range) 69 (20-91) ECOG Score: n (%) Brain Metastases: n (%) Smoking Status: n (%) No restriction No Data No Data Results Result Crizotinib 12 Month Mortality 47.5% (86/181) Duration of Therapy Median Months, (Range) Time to Treatment Change Median Months, (Range) Patients Remaining at Data Cutoff Author s Conclusion Strengths Limitations 3 Months (1-60) 4.2 Months (1-59) 72 Crizotinib had a higher 12-month mortality in the MHS compared to clinical trial results Crizotinib had a shorter duration of therapy in the MHS compared to clinical trial results ECOG score and median patient age may be confounders in the comparison of real-world to clinical trial patients Proper statistical comparisons require chart reviews which could limit value-based contracting feasibility for price reduction Real-world patient data Large sample limited patient exclusion Statistical comparison was not appropriate due to differences and confounders in patient populations Effect of ECOG performance score on results is unknown Chemotherapy initiation and adherence metrics are not readily available 13
14 Summary 1. Comparison of real-world MHS data to clinical trial results is summarized in table 4 Table 4. Results comparison13, 20 Conclusion 1. Crizotinib duration of therapy and mortality presented in clinical trials are inconsistent with the findings from the MHS population13, 20 a. The median duration of therapy was shorter in the MHS population (3 months) vs. the clinical trial populations of the PROFILE 1014 and ALEX trials (10.7 months and 10.9 months, respectively) b. Twelve-month mortality was 30% higher in the MHS (47.5%) compared to the PROFILE 1014 (16%) and ALEX trials (17.5%) c. The differences between clinical trial results and MHS findings are attributed to two potential confounders i. The PROFILE 1014 and ALEX trials restrict inclusion based on ECOG score. MHS does not restrict the use of ALK inhibitors based on level of disability ii. Median patient age was higher in the MHS (69 years) than PROFILE 1014 (52 years) and ALEX (54 years) d. The confounders reveal fundamental differences in baseline characteristics of each group. For this reason, the authors did not conduct statistical comparison between populations 14
15 Final recommendations 1. Despite unfavorable real-world results, ALK inhibitors are recommended as first-line treatment in advanced metastatic NSCLC a. ALK inhibitors effectively extend progression-free survival and duration of response compared to chemotherapy and have fewer severe adverse reactions b. Real-world patients experienced shorter durations of therapy and higher mortality than presented in clinical trials c. Although the presented real-world results are not favorable, age and ECOG score appear to influence outcomes d. Younger patients with an ECOG score of 0-1 appear to benefit most from ALK inhibitor therapy e. Future studies are needed to assess the impact of age and ECOG score on ALK inhibitor efficacy 2. This study revealed numerous challenges of comparing real-world data to clinical trial data, and the incorporation of results into potential value-based contracting solicitations a. As a health plan, evaluating only the population that meets clinical trial inclusion criteria would exclude real patients that received medication appropriately b. The statistical comparison of all real-world patients to clinical trial patients may be inappropriate due to population differences c. The challenges of this type of comparison will have to be addressed by future research in order to pursue value-based contracting 3. Future steps include a. Extending the analysis to other ALK inhibitors once utilization increases b. Conduct a Cost Effectiveness Analysis to analyze the relative cost and benefit of the ALK inhibitors 15
16 Appendices Appendix A. Abbreviations ALK Anaplastic Lymphoma Kinase OS Overall Survival NSCLC Non-Small Cell Lung Cancer PFS Progression Free Survival AUC Area Under the Curve ECOG Score Eastern Cooperative Oncology Group Performance Score WAC Price Wholesale Acquisition Price DOT Duration of Therapy ILD Interstitial Lung Disease MHS Military Health System ORR Objective Response Rate PARP Poly ADP Ribose Polymerase Appendix B. MHS crizotinib survival curve 16
17 References: 1. Non-small cell lung cancer. The American Cancer Society. Available at: Cancer.org/cancer/non-small-celllung-cancer. Accessed April 24, Alectinib: an Anaplastic Lymphoma Kinase (ALK) Inhibitor. Personalized medicine in oncology; Available at: personalizedmedonc.com/article/alectinib-an-anaplastic-lymphoma-kinase-alk-inhibitor. Accessed April 24, Mourali, J et al. Anaplastic Lymphoma Kinase Is a Dependence Receptor Whose Proapoptotic Functions Are Activated by Caspase Cleavage. Mol. Cell. Biol. 2006;26 (16): Klein, R et al. Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer. J Thorac Oncol. 2009;4 (11): Ettinger, D et al. NCCN Clinical practice guidelines in oncology: Non-Small Cell Lung Cancer. National comprehensive cancer network. Available at: Accessed April 28, Xalkori (Crizotinib) [package insert]. Pfizer. NY; Zykadia (Ceritinib) [package insert]. Novartis Pharmaceutical Corporation. NJ; Alecensa (Alectinib) [package insert]. Genentech. Tokyo, Japan; Alunbrig (Brigatinib) [package insert]. ARIAD Pharmaceuticals. Cambridge, MA; Cisplatin. Lexi-Comp Online. Wolters Kluwer Health, inc. Riverwoods, IL. Available at: online.lexi.com. Accessed 24 April Carboplatin. Lexi-Comp Online. Wolters Kluwer Health, inc. Riverwoods, IL. Available at: online.lexi.com. Accessed 24 April Wilson, F. A Functional Landscape of Resistance to LK inhibition in Lung Cancer. Cancer Cell. 2015;27(3): Solomon, B et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 2014;371; Crizotinib Lexi-Comp Online. Wolters Kluwer Health, inc. Riverwoods, IL. Available at: online.lexi.com. Accessed 28 April Ceritinib Lexi-Comp Online. Wolters Kluwer Health, inc. Riverwoods, IL. Available at: online.lexi.com. Accessed 28 April Alectinib Lexi-Comp Online. Wolters Kluwer Health, inc. Riverwoods, IL. Available at: online.lexi.com. Accessed 24 April Brigatinib Lexi-Comp Online. Wolters Kluwer Health, inc. Riverwoods, IL. Available at: online.lexi.com. Accessed 24 April Mok et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2016; 34: Kim, D et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase Positive Non Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 35: Peters, S et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non Small-Cell Lung Cancer. N Engl J Med. 2017;377;9 17
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationLUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?
LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationThe Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront? Jeffrey Zweig, MD, and Heather Wakelee, MD Abstract Therapeutic options for advanced anaplastic lymphoma
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationlimitations of the indirect evidence submitted to pcodr, perc concluded that there is considerable uncertainty on how alectinib compares with ceritinib with regard to outcomes important to decision making
More informationThe pcodr review also provided contextual information on ALK mutation testing.
only approximately 4% of NSCLC patients are expected to have the ALK mutation. perc further discussed these estimates in the context of the feasibility of implementing a funding recommendation for crizotinib.
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395
Ceritinib for previously treated anaplastic lymphoma kinase positive non- small-cell lung cancer Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta5 NICE 2018. All rights reserved.
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationFDA approves Roche s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Media Release Basel, 07 November 2017 FDA approves Roche s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationEuropean Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Media Release Basel, 21 December 2017 European Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer
Editorial ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer Viola W. Zhu 1,2, Sai-Hong Ignatius Ou 1 1 Division of Hematology/Oncology,
More informationALECENSA (alectinib) Fact Sheet
ALECENSA (alectinib) Fact Sheet What is NSCLC? ALECENSA is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Follow-up phase III data showed Roche s Alecensa helped people with ALKpositive metastatic non-small cell lung cancer live a median of almost three years without their
More informationCONTEXT OF THE RESUBMISSION EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
treatment option, there is a notable pill burden at five tablets per day. perc also noted that patients valued additional treatment options relevant to their genotype. perc, however, noted that the increased
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta406
Crizotinib for untreated anaplastic lymphoma kinase-positive e advanced non- small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta406 NICE 2018. All
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Brigatinib (Alunbrig) Reference Number: CP.PHAR.342 Effective Date: 07.17.17 Last Review Date: 05.18 Line of Business: Commercial; Medicaid Revision Log See Important Reminder at the end
More informationXalkori. Xalkori (crizotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.12 Subject: Xalkori Page: 1 of 6 Last Review Date: June 22, 2017 Xalkori Description Xalkori (crizotinib)
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationMedical Policy. MP Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Medical Policy MP 2.04.45 BCBSA Ref. Policy: 2.04.45 Last Review: 10/30/2017 Effective Date: 10/30/2017 Section: Medicine Related Policies 2.04.115 Molecular Panel Testing of Cancers to Identify Targeted
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationALECENSA (alectinib) oral capsule
ALECENSA (alectinib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMedia Release. China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Media Release China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China,
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationTreatment of ALK Positive Advanced NSCLC Fiona Blackhall PhD FRCP Medical Oncologist Manchester, UK
Treatment of ALK Positive Advanced NSCLC Fiona Blackhall PhD FRCP Medical Oncologist Manchester, UK ESMO The Christie Preceptorship in Lung Cancer March 2017 2017 : Similar incidence in women & men ADC
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationGilotrif. Gilotrif (afatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 6 Last Review Date: March 16, 2018 Gilotrif Description Gilotrif (afatinib)
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationSummary of the risk management plan (RMP) for Zykadia (ceritinib)
EMA/154751/2015 Summary of the risk management plan (RMP) for Zykadia (ceritinib) This is a summary of the risk management plan (RMP) for Zykadia, which details the measures to be taken in order to ensure
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationTitle: Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) ceritinib
Title: Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) ceritinib Produced by ERG: Warwick Evidence Authors: Joshua Pink, Assistant Professor in Health Economics, Warwick
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationMolecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Policy Number: 2.04.45 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationpcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationFDA grants Roche s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer
Investor Update Basel, 3 August 2017 FDA grants Roche s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationIs Bevacizumab (Avastin) Safe and Effective as Adjuvant Chemotherapy for Adult Patients With Stage IIIb or IV Non-Small Cell Lung Carcinoma (NSCLC)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Bevacizumab (Avastin) Safe and Effective
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationEGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA
EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA Sze Wai Chan A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationperc noted that it was challenging to interpret the data and that limited conclusions could be drawn from these non-comparative trials. The Committee discussed the likelihood of conducting a higher-quality
More informationClinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Tarceva) Reference Number: CP.PHAR74 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationAlunbrig (brigatinib) NEW PRODUCT SLIDESHOW
Alunbrig (brigatinib) NEW PRODUCT SLIDESHOW Introduction Brand name: Alunbrig Generic name: Brigatinib Pharmacological class: Kinase inhibitor Strength and Formulation: 30mg, 90mg; tabs Manufacturer: Takeda
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More information2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: September 15, 2017 Gilotrif Description Gilotrif
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Alectinib (Alecensaro) for Non-Small Cell Lung Cancer March 29, 2018
pan-canadian Oncology Drug Review Final Clinical Guidance Report Alectinib (Alecensaro) for Non-Small Cell Lung Cancer March 29, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationDM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat
DM Seminar ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat Introduction Discovery of activating mutations in kinase domain of epidermal growth factor receptor (EGFR) opened a new era of
More informationTARCEVA (erlotinib) oral tablet
TARCEVA (erlotinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPath to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationNCCP Chemotherapy Regimen. Alectinib Monotherapy
INDICATIONS FOR USE: Alectinib INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC)
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationWhen Policy Topic is covered Crizotinib may be considered medically necessary in patients 18 years or older when the following criteria are met:
Xalkori (crizotinib) Policy Number: 5.01.539 Last Review: 6/2018 Origination: 7/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for crizotinib
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationTechnology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500
Ceritinib for untreated ALK-positive non- small-cell lung cancer Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500 NICE 2018. All rights reserved. Subject to Notice of
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More information